Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

IMMUTOL

Financiado

ADVANCED ANTIGEN-SPECIFIC DENDRITIC CELL-BASED THERAPY TO RE-ESTABLISH TOLERANCE...

ADVANCED ANTIGEN-SPECIFIC DENDRITIC CELL-BASED THERAPY TO RE-ESTABLISH TOLERANCE IN IMMUNE-MEDIATED DISEASES Autoimmune diseases are currently treated with immunosuppressive and supportive therapies, which dampen inflammation, but do not stop the cause of the disease and are required life-long. Thus, there is an unmet need for safe and e... ver más

30/04/2027

FONDAZIONE TELETHO...

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

FONDAZIONE TELETHON ETS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 11 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-04-14

HORIZON-HLTH-2022-DISEASE-06-02-two-stage: Pre-clinical development of the nex... ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or...

I+D

Cerrada hace 2 años

0% 100% 100%

11 Participantes

FONDAZIONE TELETHON ETS

1.34M€ | Lider

KLINIKUM DER UNIVERSITAET RE...

907.19K€ | Participante

Stichting Sanquin Bloedvoorz...

606.41K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2009-07272 TERAPIA CON CELULAS DENDRITICAS TOLEROGENICAS EN LA ENFERMED... 254K€ Cerrado

FJCI-2017-33604 Dendritic cells in Immunotherapy 50K€ Cerrado

BES-2010-030033 TERAPIA CON CELULAS DENDRITICAS TOLEROGENICAS EN LA ENFERMED... 43K€ Cerrado

SAF2011-27330 MECANISMOS DE INDUCCION DE TOLERANCIA POR MEDIADORES DE LA R... 169K€ Cerrado

EEBB-I-12-03859 TERAPIA CON CELULAS DENDRITICAS TOLEROGENICAS EN LA ENFERMED... 10K€ Cerrado

SAF2013-48834-R ORIGEN, DESARROLLO, Y FUNCION IMMUNO REGULADORA DE CELULAS M... 163K€ Cerrado

Duración del proyecto: 48 meses Fecha Inicio: 2023-04-14
Fecha Fin: 2027-04-30

Líder del proyecto

FONDAZIONE TELETHON ETS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 6M€

Descripción del proyecto Autoimmune diseases are currently treated with immunosuppressive and supportive therapies, which dampen inflammation, but do not stop the cause of the disease and are required life-long. Thus, there is an unmet need for safe and effective therapies for these diseases, which are well-tolerated and targeting the cause of disease. Tolerogenic dendritic (DC) cell-based therapies, offer the possibility of restoring immune regulation leading to long-lasting effects. Vitamin (Vit)D3-modified tolerogenic DC have been recently applied to Multiple Sclerosis (MS) patients in Phase I trials, demonstrating safety, tolerability, feasibility, and preliminary evidence of an effect. Molecular characterization of VitD3DC from MS patients suggests that they own less tolerogenic properties than those from healthy individuals. Thus, correcting these deficiencies through gene transfer could improve their effectiveness. The aim of IMMUTOL is the fast-track development and validation of an advanced therapeutic medicinal product (ATMP) based on VitD3-modified tolerogenic DC for immunotherapy approaches. Through a multidisciplinary approach, IMMUTOL will leverage the power of tolerogenic VitD3DC-based immunotherapy to develop a more potent and durable treatment for MS and, in turn other autoimmune inflammatory diseases with an unmet medical need. In parallel, it will bring information about tolerance mechanisms and patient-specific requirements for manufacturing effective tolDC products. Results will lead to design of a clinical protocol according to the regulatory requirements for the first-in-man application of engineered tolerogenic VitD3DC in MS patients.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores